P3 Health Partners Inc

P3 Health Partners, Inc. is a population health care management company, which engages in the provision of professional support services to doctors and clinicians. The firm offers capital efficient care model, data and technology, physician leadership and community outreach tools to create enhanced patient outcomes and experiences. The company was founded by Sherif Abdou and Amir Bacchus on August 20, 2020 and is headquartered in Henderson, NV.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

P3 Health Partners Inc reports robust Q4 performance and eyes profitability in 2024

P3 Health Partners Inc demonstrated strong financial performance and strategic initiatives during the Q4 2022 earnings call, positioning the company for future growth and profitability. While facing challenges in managing costs and optimizing margins, the company remains optimistic about its financial outlook and growth prospects. By leveraging opportunities in market expansion and operational enhancements, P3 Health Partners Inc aims to achieve positive cash flow in 2024.

P3 Health Partners Inc reports improved Q1 performance and growth outlook

P3 Health Partners Inc showed improved financial performance and operational metrics in Q1.
The company is on track towards profitability, with a focus on growth and healthcare transformation.
Challenges include managing EBITDA losses, COVID impact, and provider relationships.
Opportunities lie in further improving metrics, expanding in newer markets, and enhancing care management.

P3 Health Partners Inc reports strong Q2 earnings and growth opportunities

P3 Health Partners Inc (PIII) demonstrated positive financial performance in Q2 2023, with strong revenue growth and improved margins.
The company's focus on operational efficiency, quality improvements, and growth objectives positions it well for future success.
While facing challenges in managing expenses and achieving profitability, P3 Health Partners Inc (PIII) has opportunities for growth and market expansion.
Overall, the company's sustained demand, efficient operations, and progress towards profitability indicate a promising outlook for stakeholders.

P3 Health Partners Inc reports solid Q3 results, eyes growth

P3 Health Partners Inc delivered a strong performance in Q3, focusing on revenue growth, cost management, and profitability.
While facing challenges such as timing issues and payer negotiations, the company remains optimistic about its future prospects.
Opportunities for growth include expanding partnerships, optimizing operational efficiency, and providing clearer financial guidance to stakeholders.
Overall, PIII's strategic initiatives position it well for continued success, with a positive outlook for 2024 and beyond.

P3 Health Partners reports strong 2023 growth and positive 2024 outlook

P3 Health Partners Inc delivered robust financial performance in 2023.
Strategic initiatives led to improved margins and revenue growth.
Challenges include managing expenses and potential regulatory changes.
Opportunities lie in partnerships, persistency rates, and revenue expansion.

P3 Health Partners reports strong Q1 earnings, eyes AI growth

P3 Health Partners Inc's Q1 2024 showed strong revenue growth and operational efficiencies.
The company is confident in achieving its EBITDA guidance through strategic partnerships and focus on high-risk populations.
Challenges include managing cash flow, capital requirements for growth, and effective high-risk population management.
Opportunities lie in AI partnerships, data analytics tools, and deeper provider engagement for better care outcomes.

P3 Health Partners reports robust Q2 results and eyes growth

P3 Health Partners showed strong performance in Q2 with revenue growth, cost reduction, and improved EBITDA loss. The company's focus on expense management and balance sheet strength position it well for future growth. Challenges remain in managing medical costs and achieving profitability, but opportunities for expansion and improved financial performance are evident.

P3 Health Partners reports Q3 loss, plans improvements for 2025

P3 Health Partners Inc faced challenges in Q3 2024 with a $71 million adjusted EBITDA loss, driven by retroactive adjustments and high medical utilization. Despite this, the company plans significant improvements in contracts, efficiency, and data analytics for 2025. Opportunities exist in optimizing working capital, strategic financing, and focusing on high-performance markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

P3 Health Partners (PIII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will P3 Health Partners Inc. (PIII) Report Negative Earnings Next Week? What You Should Know

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for second quarter 2024 and file its Quarterly Report on Form 10-Q on Wednesday, August 7, 2024. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health Se.

P3 Health Partners Schedules Second Quarter 2024 Earnings Release and Conference Call

SAN FRANCISCO--(BUSINESS WIRE)--Innovaccer Inc., a leading healthcare AI company, announced a new strategic partnership with P3 Health Partners, (NASDAQ: PIII), a patient-centered, physician-led population health management company revolutionizing care delivery for Medicare patients. This partnership marks a significant milestone in advancing value-based care initiatives aimed at improving patient outcomes, optimizing costs, and enhancing the patient and clinician experience. P3 Health Partners.

P3 Health Partners Forms Strategic Partnership with Innovaccer to Drive Value-Based Care and Patient Experience

P3 Health Partners is collaborating with healthcare providers in five states, providing assistance for compensation. The company's revenue has been steadily growing, but has not yet been profitable. However, profitability is expected in 2024. The recent announcement of a new CEO may bring renewed attention to PIII stock.

P3 Health Partners: Moving In The Right Direction In 2024

P3 Health Partners (NASDAQ: PIII ) stock is falling on Tuesday after the company sold shares and warrants to institutional investors in a recent offering. P3 Health Partners reveals in a filing with the Securities and Exchange Commission (SEC) that it issued roughly 67.4 million shares of PIII stock to institutional investors.

Why Is P3 Health Partners (PIII) Stock Down 4% Today?

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (Nasdaq: PIII), a patient- centered and physician-led population health management company (the “Company”), today announced that it has entered into definitive agreements to sell securities in a private placement with certain institutional investors. The lead institutional investors in the private placement are affiliates of Chicago Pacific Founders (“CPF”). The transaction is expected to result in gross proceeds of approximately $42.2 m.

P3 Health Partners Inc. Announces Approximately $42.2 Million Private Placement

P3 Health Partners Inc. (NASDAQ:PIII ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Ryan Halsted - Gilmartin Group Sherif Abdou - Strategic Advisor Atul Kavthekar - CFO Amir Bacchus - CMO Aric Coffman - CEO Bill Bettermann - COO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Josh Raskin - Nephron Research Jenny Shen - BTIG Gary Taylor - TD Cowen Jack Senft - William Blair Operator Hello and welcome to the P3 Health Partners' First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

P3 Health Partners Inc. (PIII) Q1 2024 Earnings Call Transcript

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), today reported that the Board of Directors (the “Board”) (including the independent members of the Board) approved the award of employment inducement equity grants to Aric Coffman, M.D. in connection with his agreement to serve as the Company's Chief Executive Officer and President as follows: effective as of May 9, 2024, the grant of an employment inducement stock option award covering 12,100,000.

P3 Health Partners Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the first quarter ended March 31, 2024. “We reported a strong Q1 which exceeded our internal expectations on the top-line. We believe that we are on track to achieve our full year 2024 guidance,” said Dr. Sherif Abdou, Co-Founder of P3. “I am thrilled to welcome Aric to the team and.

P3 Health Partners Announces First Quarter 2024 Results

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), today named Dr. Aric Coffman as P3's Chief Executive Officer, effective as of May 8, 2024, succeeding Dr. Sherif Abdou, P3's Co-Founder. Dr. Abdou will continue to serve as a Strategic Advisor to P3, and a member of the Company's Board of Directors working closely with Dr. Coffman to ensure a smooth transition. Dr. Coffman is an exceptional physician leader with a proven track record of success in.

P3 Health Partners Names Dr. Aric Coffman as CEO

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for first quarter 2024 and file its Quarterly Report on Form 10-Q on Wednesday, May 8, 2024. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health First.

P3 Health Partners Schedules First Quarter 2024 Earnings Release and Conference Call

P3 Health Partners Inc. (PIII) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that management is scheduled to present at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 1:30 pm Eastern Time. A webcast of the presentation will be available on P3's Investor Relations Website: https://ir.p3hp.org/. A replay will be available on P3's investor relations webpage for 30 d.

P3 Health Partners to Present at the 23rd Annual Needham Virtual Healthcare Conference

P3 Health Partners Inc. (PIII) Q4 2023 Earnings Call Transcript

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and affirmed its 2024 guidance. “Top line results for 2023 were strong as the team executed and delivered with revenue of approximately $1.27 billion, representing 21% growth and exceeding the top end of our guidance range. We.

P3 Health Partners Announces Fourth Quarter and Full Year 2023 Results

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, announces that the Company plans to release its financial results for the fourth quarter and full year 2023 on March 28, 2024 and is reaffirming its 2024 guidance. The Company expects to file its Annual Report on Form 10-K for the year ended December 31, 2023, with the SEC within the extension period provided by Rule 12b-25.

P3 Health Partners to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that leadership is scheduled to present at the KeyBanc LifeSciences & Medtech Investor Forum virtually on Tuesday, March 19, 2024 at 3:45pm ET. A webcast of the presentation will be available on P3's Investor Relations Website: https://ir.p3hp.org/. A replay will be available on P3's investor relations we.

P3 Health Partners to Present at the KeyBanc LifeSciences & Medtech Investor Forum

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced management will participate in the upcoming Jefferies Value Based Healthcare Summit in Miami Beach, Florida. Management is scheduled to host investor meetings on Monday, March 11th, 2024. About P3 Health Partners (NASDAQ: PIII): P3 Health Partners Inc. is a leading population health management company committed to transformin.

P3 Health Partners to Participate in the Jefferies Value Based Healthcare Summit

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that management is scheduled to present at the TD Cowen 44th Annual Health Care Conference in Boston on Monday, March 4, 2024 at 10:30 am Eastern Time. A webcast of the fireside chat will be available on P3's Investor Relations Website: https://ir.p3hp.org/. A replay will be available on P3's investor relations webpage for 30.

P3 Health Partners to Present at the TD Cowen 44th Annual Healthcare Conference

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that it will participate in the upcoming 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Management is scheduled to host investor meetings on Tuesday, February 13th, and Wednesday February 14th, 2024. About P3 Health Partners (NASDAQ: PIII): P3 Health Partners Inc. is a lea.

P3 Health Partners to Participate in The 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

P3 Health Partners shares jumped in Wednesday premarket trading after the healthcare company guided for a strong rise in 2024 revenue and positive underlying earnings (EBITDA) as it grows its Medicare Advantage member base. In an update ahead of a presentation at a J.P.

P3 Health Partners stock pops on bullish 2024 revenue guidance

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, is participating in J.P. Morgan's 42nd Annual Healthcare Conference, being held in San Francisco, CA from January 8-11, 2024. In advance of the associated meetings and presentation, P3 is reaffirming guidance for 2023 and announcing guidance for 2024. “We made significant strides in 2023 and expect to achieve meaningful prof.

P3 Health Partners Reaffirms Guidance for 2023 and Announces Guidance for 2024

Clover Health Investments

Talkspace

Zacks Medical Info Systems industry stocks like Clover Health Investments (CLOV), Talkspace (TALK) and P3 Health Partners (PIII) are expected to gain from the new normal trends.

3 Medical Info Systems Stocks to Buy as Industry Rebounds

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, announces that it will participate at the upcoming J.P. Morgan Healthcare Conference in San Francisco, California. Management will give a presentation on Wednesday, January 10, 2024, at 1:30 PM Pacific Time. A webcast of the live event will be available on the P3 Investor Relations website at ir.p3hp.org. A replay will be available shortly a.

P3 Health Partners to Present at the 42nd Annual J.P. Morgan Healthcare Conference

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that leadership will participate in the BTIG Digital Health Forum, being held virtually, on Monday, November 20, 2023, including a panel discussion with Dr. Sherif Abdou, Chief Executive Officer and Co-founder of P3, at 12:00 p.m. PT/3:00 p.m. ET. About P3 Health Partners (NASDAQ: PIII): P3 Health Partners In.

News for P3 Health Partners Inc Stock (PIII)